Back in Januaray 2017, the Ontario government dedicated an additional $5 million to help smokers quit: news.ontario.ca/mohltc/en/2017/01/new-supports-to-help-people-in-ontario-quit-smoking.html
$2.5 million is dedicated towards "Quit Cards" which reimburse pharmacies up to $450 in nicotine replacement therapies.
These quit cards are currently being distributed via in-patient hospitals and cancer centres. Patients bring their quit card to their local pharmacy to obtain free NRT.
Adjudication details can be found at: ottawamodel.ottawaheart.ca/quitcard
[If you have any questions or difficulties processing, contact STI Customer Support at 1-877-790-1991 (7:30am-5pm EST). Process the claim using the QUIT CARD set as PRIMARY PAYER. Use “99999” in the PRESCRIBER ID field and “QUIT CARD” in the PRESCRIBER NAME field.]
After the pilot, the cards *may* be distributed via family physicians and pharmacists as well.
Blexten (BLEKS-ten, bilastine) and Rupall (ROO-pal, rupatadine) are two new antihistamines on prescription.
"BLEXTEN (bilastine 20 mg oral tablet) is a second generation antihistamine drug for the treatment of Seasonal Allergic Rhinitis (SAR) and Chronic Spontaneous Urticaria (CSU). BLEXTEN exerts its effect as a selective histamine H1 receptor antagonist, and has an effectiveness comparable to cetirizine, fexofenadine and desloratadine."
"Rupatadine is a new second-generation antihistamine and platelet-activating factor (PAF) antagonist."
Blexten DIN is 2454130
Rupall DIN is 2456451
You can also read more on Canadian Pharmacist's Letter; February 2017; Vol: 33
News that has been personally selected by the Editorial team.